Hutchison Medipharma Starts Clinical Trial of Second Cancer Drug
2/1/2011 12:34:59 PM
February 1, 2011 -- Hutchison MediPharma, the drug discovery arm of Chi-Med, has begun a Phase I trial of its second anti-angiogenesis cancer drug candidate, fruquintinib. The first molecule, sulfatinib (HMPL-012), began clinical trials in April of 2010. According to Hutchison, fruquintinib showed “potent” anti-angiogenesis activity in pre-clinical testing. More details....